Fractalkine upregulates inflammation through CX3CR1 and the Jak-Stat pathway in severe acute pancreatitis rat model

Inflammation

Volumn 35, Issue 3, 2012, Pages 1023-1030

  Huang, Li Ya ^b   Chen, Ping ^a   Xu, Ling Xiao ^a   Zhou, Yu Fen ^a   Zhang, Yong Ping ^a   Yuan, Yao Zong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Chemokine; CX3CR1; Fractalkine; Jak Stat; Severe acute pancreatitis

Indexed keywords

CERULETIDE; CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; JANUS KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; SMALL INTERFERING RNA; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PANCREATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CAERULEIN; CELL LINE; CHEMOKINE CX3CL1; INFLAMMATION; INFLAMMATION MEDIATORS; JANUS KINASES; PANCREATITIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHEMOKINE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

RATTUS;

EID: 84863792755     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-011-9406-5     Document Type: Article

References (29)

1. Harrison, D.A., G. D'Amico, and M. Singer. 2007. The Pancreatitis Outcome Prediction (POP) Score: a new prognostic index for patients with severe acute pancreatitis. Critical CareMedicine 35: 1703-1708. (Pubitemid 46985873)
2. Bazan, J.F., K.B. Bacon, G. Hardiman, et al. 1997. A new class of membrane bound chemokine with a CX3C motif. Nature 385: 640-644.
3. Volin, M.V., J.M. Woods, M.A. Amin, M.A. Connors, L.A. Harlow, and A.E. Koch. 2001. Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. The American Journal of Pathology 159: 1521-1530. (Pubitemid 32947980)
4. Lee, S.J., S. Namkoong, Y.M. Kim, et al. 2006. Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and PI3K/Akt/eNos-dependent signal pathways. American Journal of Physiology-Heart and Circulatory Physiology 291: H2836-H2846. (Pubitemid 44904084)
5. Efsen, E., C. Grappone, R.M. DeFranco, et al. 2002. Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. Journal of Hepatology 37: 39-47. (Pubitemid 34713053)
6. Segerer, S., E. Hughes, K.L. Hudkins, M. Mack, T. Goodpaster, and C.E. Alpers. 2002. Expression of the fractalkine receptor (CX3CR1) in human kidney disease. Kidney International 62: 488-495. (Pubitemid 34779759)
7. Kishimoto, T., T. Taga, and S. Akira. 1994. Cytokine signal transduction. Cell 76: 253-262. (Pubitemid 24046688)
8. Igaz, P., S. Toth, and A. Falus. 2001. Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice. Inflammation Research 50: 435-441. (Pubitemid 32889442)
9. Rawlings, J.S., K.M. Rosler, and D.A. Harrison. 2004. The JAK/STAT signaling pathway. Journal of Cell Science 117: 1281-1283. (Pubitemid 38559804)
10. Levitzki, A., and A. Gazit. 1995. Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782-1788.
11. Chen, P., Y. Yuan, S. Wang, L. Zhan, and J. Xu. 2006. Captopril, an angiotensin converting enzyme inhibitor, attenuates the severity of acute pancreatitis in rats by reducing expression of matrix metalloproteinase. The Tohoku Journal of Experimental Medicine 209: 99-101.
12. Yu, J.H., K.H. Kim, and H. Kim. 2006. Suppression of IL-1βexpression by the Jak 2 inhibitor AG490 in cerulein-stimulated pancreatic acinar cells. Biochemical Pharmacology 72: 1555-1562. (Pubitemid 44755147)
13. Grewal, H.P., E.L. Mohey, A. Din, L. Gaber, M. Kotb, and A.O. Gaber. 1994. Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-alpha polyclonal antibody. Am. J. Sug 167: 214-218.
14. Zhang, Xi-Ping, J. Zhang, Mei-Li Ma, et al. 2010. Pathological changes at early stage of multiple organ injury in a rat model of severe acute pancreatitis. Hepatobiliary & Pancreatic Diseases International 9: 83-85.
15. Zhang, Q., K. Shimoya, K. Temma, et al. 2004. Expression of fractalkine in the fallopian tube and of CX3CR1 in sperm. Human Reproduction 19: 409-414. (Pubitemid 38220015)
16. Ancuta, P., R. Rao, A. Moses, A. Mehle, et al. 2003. Fractalkine preferentially mediates arrest and migration of CD16 monocytes. Journal of Experimental Medicine 197: 1701-1707. (Pubitemid 36745345)
17. Fraticelli, P., M. Sironi, G. Bianchi, et al. 2001. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. Journal of Clinical Investigation 107: 1173-1181. (Pubitemid 32422914)
18. Umehara, H., E.T. Bloom, T. Okazaki, Y. Nagano, O. Yoshie, and T. Imai. 2004. Fractalkine in vascular biology: from basic research to clinical disease. Arteriosclerosis, Thrombosis, and Vascular Biology 24: 34-40. (Pubitemid 38082409)
19. Haskell, C.A., M.D. Cleary, and I.F. Charo. 2000. Unique role of the chemokine domain of fractalkine in cell capture: kinetics of receptor dissociation correlate with cell adhesion. Journal of Biological Chemistry 275: 34183-34189.
20. Garton, K.J., P.J. Gough, C.P. Blobel, et al. 2001. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). Journal of Biological Chemistry 276: 37993-38001.
21. Combadiere, C., S. Potteaus, J.L. Gao, et al. 2003. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107: 1009-1016. (Pubitemid 36258725)
22. Eriksson, E.E. 2004. Mechanisms of leukocyte recruitment to atherosclerosclerotic lesions: future prospects. Current Opinion in Lipidology 15: 5911-5918.
23. Duxbury, M.S., E. Matros, H. Ito, M.J. Zinner, S.W. Ashley, and E. E. Whanq. 2004. Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Annals of Surgery 240(4): 667-674.
24. Filleur, S., A. Courtin, S. Ali, et al. 2003. siRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Research 63(14): 3919-3922. (Pubitemid 36917906)
25. Sioud, M. 2010. Advances in RNA sensing by the immune system: separation of siRNA unwanted effects from RNA inference. Methods in Molecular Biology 629: 33-52.
26. Brummelkamp, T.R., R. Bernards, and R. Agami. 2002. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2(3): 243-247. (Pubitemid 41043979)
27. Chetty, C., P. Bhoopathi, P. Joseph, S. Chittivelu, Js Rao, and S. Lakka. 2006. Adenovirus -mediated siRNA against MMP-2 suppresses tumor growth and lung metastasis in mice. Molecular Cancer Therapeutics 5(9): 2289-2299. (Pubitemid 44530466)
28. Kisseleva, T., S. Bhattacharya, J. Braunstein, and C.W. Schindler. 2002. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285: 1-24. (Pubitemid 34246317)
29. Pelletier, S., F. Duhamel, P. Coulombe, M.R. Popoff, and S. Meloche. 2003. Rho family GTPase are required for activation of Jak/Stat signaling by G protein couple receptors. Molecular and Cellular Biology 23: 1316-1333. (Pubitemid 36177040)